Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UCB/Sanofi Xyzal approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

UCB and Sanofi-Aventis plan to launch the antihistamine Xyzal (levocetirizine) in the U.S. in time for the fall allergy season, the companies said. FDA approved the once-daily H1 receptor antagonist May 25 for the relief of symptoms associated with seasonal and perennial allergic rhinitis and for the treatment of uncomplicated skin manifestations of chronic urticaria in adults and children 6 years of age and older. Firms plan to jointly promote Xyzal in the U.S. using a combined field force of 1,000 sales reps. Timing of the launch will fall just ahead of when UCB/Pfizer's Zyrtec (cetirizine) is scheduled to go off patent later this year. However, UCB/Sanofi could face competition from over-the-counter H1 receptor antagonists such as loratadine (Schering-Plough's Claritin and generics). Johnson & Johnson is planning to launch OTC Zyrtec in late 2007 after acquiring the OTC licensing rights through its purchase of Pfizer Consumer Healthcare in December...

You may also be interested in...

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.

Balancing Innovation And Safety – The US and Australian Medtech Regulatory Systems Compared

Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts